Role of virechana karma in metabolic syndrome- Clinical trial
Sharma Priyanka, Srivastava Alok, Shukla Gyanendra Datta
Department of Panchakarma, Rishikul Campus, Haridwar, U.A.U.
Tiwari Shashi Kant
Department of Roga Evam Vikriti Vigyana, Rishikul Campus, U.A.U
Abstract
Metabolic Syndrome is a constellation of several factors like hyperglycemia, raised blood pressure, insulin resistance, dyslipidemia, and central obesity. Among these factors central obesity & insulin resistance are the dominant parameters of this collection. In today’s era its prevalence is rising rapidly and it has a high socioeconomic burden. Being the major risk factor for Cardio Vascular Disease and Type 2 Diabetes Mellitus, it is the need of the hour to find a safe and cost effective remedy for Metabolic Syndrome. Santarpana Nimittaj Vikara in Ayurvedic Classics can be correlated to Metabolic Syndrome and Virechana Karma is an effective measure which helps in cleansing congested Strotas and removing vitiated Dosha hence pacifying the symptoms of Metabolic Syndrome. Patients of either sex in the age group of 20 to 60 years, fulfilling the study criteria were included in the study. Two sittings of Virechana Karma were administered with 15 day gap in between. Highly significant in all criteria except Blood sugar fasting. Conclusion: Virechana Karma is an ideal therapy for Metabolic Syndrome.
Metabolic Syndrome, Virechana Karma, Santarpana Nimittaj Vikara, Dosha, Strota, Type 2 Diabetes Mellitus
Miranda, P.J., DeFronzo, R.A., Califf, R.M. and Guyton, J.R. 2005. Metabolic syndrome: definition, pathophysiology, and mechanisms. Am Heart J, 149(1): 33-45.
Expert Panel on Detection, Evaluation THBCA: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). J-AM MED ASSOC 2001, 285(19):2486–2497.
Grundy, S.M., Cleeman, J.I., Daniels, S.R., Donato, K.A., Eckel, R.H. and Franklin, B.A. 2005. Diagnosis and management of the metabolic syndrome. Circulation 112(17):2735–2752.
Meigs, J.B. 2002. Epidemiology of the metabolic syndrome, Am J Managed Care 8(11), SUPP/1): 283–292.
Gupta, A., Gupta, R., Sarna, M., Rastogi, S., Gupta, V. and Kothari, K. 2003. Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population. Diabetes Res Clin Pract, 61(1): 69–76.
Ford, E.S., Giles, W.H. and Dietz, W.H. 2002. Prevalence of the metabolic syndrome among US adults. JAMA: J Am Med Assoc, 287(3): 356–359.
Balkau, B., Vernay, M., Mhamdi, L., Novak, M., Aronde, D. and Vol, S. 2003. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French DESIR study. Diabetes & Metabolism, 29(5):526–532.
Ramachandran, A., Snehlata, C., Satyavani, K., Sivasankari, S. and Vijay, V. 2003. Metabolic syndrome in urban Asian Indian adults—a population study using modified ATP III criteria. Diabetes Res Clin Pract, 60(3):199–204.
Meigs, J.B. 2000. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol, 152(10):908–911.
Shastri Datta Rajeshwara, 2009a. Upadhyaya Yadunandan, Pandeya Sahaya Ganga, and Gupta Dasa Banarasi, Mishra Brahmashankara (editors) Commentary: Vidhyotani teka of Kasi Nath Sastri & Gorakha Nath Chaturvedi of Charak Samhita of Agnivesha, Sutrasthan, chapter 23, verse no. 8, Varanasi: Chaukhambha Bharti Academy:437.
Shastri Datta Rajeshwara, 2009b. Upadhyaya Yadunandan, Pandeya Sahaya Ganga, and Gupta Dasa Banarasi, Mishra Brahmashankara (editors) Commentary: Vidhyotani teka of Kasi Nath Sastri & Gorakha Nath Chaturvedi of Charak Samhita of Agnivesha, Siddhisthan, chapter 2, verse no.13 , Varanasi: Chaukhambha Bharti Academy:981.
Chaudhary Nidhi, 2017a. Clinical evaluation of Virechana in management of Metabolic Syndrome, MD Thesis; Dept. of Panchakarma; Rishikul campus; UAU: 68.
Tiwari K Shashi (2018). Characterization of the urine of patients of Metabolic Syndrome and Prediabetics and its correlation with Different Types of Prameha: Review of Ayurvedic Literature, PhD Thesis, Dept. of Vikriti Vigyana, I.M.S., B.H.U., Varanasi: 5.
Chaudhary Nidhi, 2017b. Clinical evaluation of Virechana in management of Metabolic Syndrome, MD Thesis; Dept. of Panchakarma; Rishikul campus; UAU: 71.
Chaudhary Nidhi 2017c. Clinical evaluation of Virechana in management of Metabolic Syndrome, MD Thesis; Dept. of Panchakarma; Rishikul campus; UAU: 73.
Sharma Priyanka, Srivastava Alok, Tiwari Shashi Kant and Shukla Gyanendra Datta (2019). Role of virechana karma in metabolic syndrome- Clinical trial. Environment Conservation Journal, 20(SE), 25-29.
This work is licensed under a Creative Commons Attribution-Non Commercial- 4.0 International License (CC BY- NC 4.0)
© ASEA
Received: 03.10.2019
Revised: 20.10.2019
Accepted: 04.10.2019
First Online: 13.12. 2019
Publisher Name: Action for Sustainable Efficacious Development and Awareness (ASEA)
Print : 0972-3099
Online :2278-5124